We describe the identification of a novel missense mutation in the second zinc finger of KLF1 in two siblings who, based on their genotype, are predicted to suffer from beta thalassemia major but are, in fact, transfusion-free and in good health. These individuals, as well as two additional members of the same family also carrying this KLF1 mutation, exhibit high levels of fetal hemoglobin (HbF). KLF1 is an erythroid transcription factor, which plays a critical role in the regulation of the developmental switch between fetal and adult hemoglobin by regulating the expression of a multitude of genes including that of BCL11A. The mutation appears to be the main candidate responsible for the beta thalassemia-ameliorating effect as this segregates with the observed phenotype and also exogenous expression of the KLF1 mutant protein in human erythroid progenitor cells resulted in the induction of γ-globin, without, however, affecting BCL11A levels. This report adds to the weight of evidence that heterozygous KLF1 mutations can ameliorate the severity of the β-thalassemia major phenotype.
The erythroid-specific transcription factor KLF1 is a crucial regulator of the γ-to β-globin switching (Borg et al., 2010; Zhou, Liu, Sun, Pawlik, & Townes, 2010) . KLF1 (also known as EKLF) is a zinc finger DNA-binding protein that was first described two decades ago by Miller and Bieker (1993) . KLF1 has two distinct domains, an Nterminal trans-activating proline-rich domain and a C-terminal zinc finger domain, which binds to the DNA sequence motif 5′-CCMCRCCCN-3′. Such a motif is located in the regulatory regions of many erythroid-specific genes including the regulatory region of the β-globin gene. The KLF1 zing finger domain consist of three zinc fingers which are essential for the regulation of KLF1 target genes (Siatecka & Bieker, 2011) . One of the functions of KLF1 is regulation of the developmental switch between fetal and adult hemoglobin.
KLF1 indirectly regulates γ-globin expression by directly regulating the expression of the transcription factor BCL11A (Borg et al., 2010; Zhou et al., 2010) . In humans, mutations in KLF1 have been associated with hematological changes and disorders such as the hereditary persistence of fetal hemoglobin (HPFH), the rare In(Lu) blood group phenotype, congenital dyserythropoietic anemia (CDA) type IV, and increased levels of zinc protoporphyrin (Kountouris et al., 2014; Perkins et al., 2016; Stamatoyannopoulos, 2005) .
Reports on the different KLF1 mutations and the various associated phenotypes have revealed, but also raised questions regarding, the role of KLF1 in human erythropoiesis. Here, we describe and partially characterize a novel KLF1 mutation, p.Ser323Leu, which is responsible for increased levels of HbF in a Cypriot family and appears to have an ameliorating effect on the β-thalassemia major phenotype resulting from the homozygous IVS1-110; HBB: c.93-21 G > A mutation. This is in agreement with an earlier report showing that seven heterozygous KLF1 mutations have the potential to modulate the clinical and hematological severity of β-thalassemia (Liu et al., 2014) .
However, unlike the family presented here, the patients in the report by Liu et al. (2014) exhibited extended transfusion-free survival rather than transfusion independence.
| DESIGN AND METHODS

| Patients and donors under study
Blood samples were collected from a Cypriot family, whose members exhibited unusually high levels of HbF, for hematological and genetic analyses carried out as part of a series of diagnostic tests.
Subsequently, in the course of the current study, additional genetic analyses were performed on the original DNA samples. Blood samples were also collected from healthy donors for the culture of 
| DNA preparation
Genomic DNA was isolated from peripheral blood using the Gentra Puregene Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The DNA concentration and purity were measured using the Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE).
| Genotyping analysis
All family members were genotypically screened for the presence of mutations at the HBA1, HBA2 (α-globin), and HBB (β-globin) genes as described before (Kountouris et al., 2016) . For the investigation of the unusually high levels of HbF, we sequenced (Sanger sequencing) the KLF1 gene (promoter region, 5′-UTR, coding region, flanking splice junctions, and 238 bp of the 3′-UTR) and the promoter regions of the HBG1 and HBG2 (γ-globin) genes. The primers used for polymerase chain reaction (PCR) amplification and DNA sequencing are summarized in Table S1 . The presence of deletional HPFH was tested by multiplex ligation-dependent probe amplification (MLPA; Harteveld et al., 2005) . In addition, family members were genotyped by SNapShot minisequencing assay for 12 SNPs at the BCL11A gene and 16 SNPs at the HBS1L-MYB intergenic region, which have been associated with variable HbF levels in a number of different populations (Fanis, Kousiappa, Phylactides, & Kleanthous, 2014) .
| Culture of erythroid progenitors and cell lines
Erythroblasts derived from peripheral blood mononuclear cells were immunomagnetically separated using the CD34 MicroBead kit (Miltenyi Biotec Inc., Auburn, CA), expanded and differentiated as described before (Breda et al., 2012) . 293T and HEL cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco, Life Technologies, Paisley, UK) and Roswell Park Memorial Institute (RPMI)-1640 cell culture medium, respectively, supplemented with 10% fetal bovine serum (Gibco, Life Technologies).
| Transient transfection
Transient transfections in 293T cells and western blot analyses were performed as described previously (Fanis et al., 2012) o test the vectors for the expression of the wild-type and mutant HA-tagged KLF1. Briefly, 293T cells were cultured in 6-well plate dishes (Costar, Corning, NY) and after 24 hr were transfected with 4 μg of plasmid DNA using polyethylemine (PEI, Polysciences, Warrington, PA). Four hours after transfection, the culture medium was refreshed and the cells were lyzed for western blot analysis 48 hr later.
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| Western blot analysis and protein quantification
After protein transfer, the nitrocellulose membranes were blocked in 1% bovine serum albumin (BSA), incubated with the appropriate primary antibodies and developed using enhanced chemiluminescence. The membranes were probed with the following primary antibodies: HA (monoclonal F7, sc-7392), γ-globin (monoclonal 51-7, sc-21756) and BCL11A (polyclonal H-116, sc-366825) obtained from Santa Cruz Biotechnology (Santa Cruz, CA), KLF1 (ab2483) from Abcam (Cambridge, MA), and β-ACTIN (monoclonal AC-15, A1978) from Sigma (St. Louis, MO). Horseradish peroxidase (HRP)-conjugated IgG rabbit anti-goat, goat antimouse, and goat antirabbit (Jackson ImmunoResearch, PA) secondary antibodies were used. The anti-KLF1 antibody was used in 1:500 dilution in TBS/Tween, the anti-γ-globin and the anti-HA antibodies were used in a dilution of 1:1,000 in TBS/Tween, and the anti-ACTIN antibody was used in 1:10,000 dilution in a solution of 1% nonfat dried milk in TBS/Tween. Secondary antibodies were used in a 1:20,000 dilution in nonfat dried milk in TBS/Tween. The levels of each protein were normalized with the corresponding β-ACTIN loading control within the same immunoblot. To avoid repeated blotting and stripping of the immunoblots, the immunoblots were cut into strips containing the proteins of interest, which were then probed with the appropriate primary antibody. Details of the procedure are provided in Figure S4 .
Visualization of the immunoblots and acquisition of the images were carried out separately for each immunoblot strip using the UVP BioSpectrum Imaging System (UVP, LLC, Upland, CA). Dynamic total time exposure settings were used, with binning set at 12.1MP, 149% and 1 × 1 interpolation. Exposure times varied depending on the primary antibody used. For anti-ACTIN, a 30 s, single-frame exposure was used. For anti-BCL11A a 2-min exposure was used, whereas for anti-HA and for anti-KLF1 a 5-min exposure was used. For exposure times longer than 2 min, multiple frames were taken.
Quantification of the protein levels was performed using the ImageJ software (National Institutes of Health, http://rsb.info.nih. gov/ij/).
2.7 | Plasmid constructs and lentivirus-mediated overexpression and knockdown of the wt and mutant KLF1 genes
The coding sequence of the human KLF1 gene was amplified from K562 cell line complementary DNA (cDNA) by PCR using the Phusion High-Fidelity DNA polymerase (New England Biolabs, Ipswich, MA), cloned into the pMT2_HA plasmid using SalI and EcoRI restriction sites and verified by sequencing. The c.968C>T p.Ser323-Leu mutation was generated using the QuikChange site-directed mutagenesis kit (Agilent technologies, Santa Clara, CA) using the oligonucleotide 5′-GAGATTCGCGCGCTTGGA CGAGCTGACCC-3′ and its complement. Expression of the wild-type and mutant HAtagged KLF1 was tested by transient transfection in 293T cells. The wild-type and the HA-tagged p.Ser323Leu mutant KLF1 were subcloned into the modified pRRLsin.sPPT.CMV.GFP.Wpre lentiviral vector (Follenzi, Sabatino, Lombardo, Boccaccio, & Naldini, 2002) using the XbaI and SalI restriction sites. Three clones targeting the human KLF1, obtained from the TRC Mission short hairpin RNA (shRNA) library, were used for knockdown experiments, as well as a nontargeting shRNA control clone. The TRC shRNA clones are described in Table S2 . Lentivirus was produced by transient transfection of 293T cells and transduced into erythroid progenitor cells as described before (Zufferey, Nagy, Mandel, Naldini, & Trono, 1997 ).
2.8 | In silico prediction and structural modeling of the c.968C>T p.Ser323Leu mutated KLF1 zing finger domain Prediction of the effect of the amino acid substitution on protein function was performed using the PredictSNP program using the default settings (Bendl et al., 2014) . The protein structure prediction program I-TASSER (Roy, Kucukural, & Zhang, 2010; Yang et al., 2015; Zhang, 2008) was used to predict the structure of the wild-type and mutated zinc finger domain of KLF1. As a template for the prediction we used the solved structure of protein WT1 complexed with DNA (PDB ID: 2PRT), as it was previously described as the best candidate for constructing a prediction model for KLF1 (Arnaud et al., 2010) .
The default settings of I-TASSER were utilized. The confidence score of the I-TASSER wild-type KLF1 structure prediction was 0.93 with a structural similarity TN score of 0.84 ± 0.08. The confidence score of the I-TASSER p.Ser323Leu mutated KLF1 structure prediction was 0.92 with a structural similarity TN score of 0.84 ± 0.08. Predicted structures of the wild-type and mutant KLF1 were visualized using the PyMOL software (The PyMOL Molecular Graphics System, Version 1.1 Schrödinger, LLC).
| Statistical analysis
All statistical analyses were performed with GraphPad Prism 6 software. The p values <.05 were considered statistically significant.
| RESULTS
| Clinical features
During an update study on the status of β-thalassemia in Cyprus (Kountouris et al., 2016) , we identified two individuals who were homozygous for the β-thalassemia major IVS1-110; HBB: c.93-21G>A mutation but were phenotypically healthy, with near-normal levels of total hemoglobin and extremely high hemoglobin F (HbF) levels (63-66.2%). Interestingly, the two individuals (II.1 and II.2) were siblings ( Figure 1a ), whereas two additional members of the same family (I.1 and III.2) exhibited high levels of HbF. The clinical features and genotypic information on all family members are presented in Table 1 . Initial hematological tests on subjects II.1 and II.2 painted a picture of mild microcytic, hypochromic anemia, that is, typical of beta thalassemia carriers (trait) in terms of the levels of total hemoglobin, red blood cell (RBC) counts, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC). Notable exceptions were the extremely high levels of HbF and the normal levels of HbA 2 . Family members I.1 and III.2, who were heterozygous for the IVS1-110 mutation and for the novel KLF1 mutation (see section "Genetic features" below), presented a picture typical of beta thalassemia trait, including raised HbA 2 levels but had higher than normal levels of HbF (8.5% and 6.5%, respectively). Subject I.1 had passed away at an advanced age due to natural causes and subject II.2 had passed away at the age of 62 due to breast and liver cancer. Her medical records indicated that she had developed osteoporosis at the age of 47 and had undergone cholecystectomy at the age of 46. She had no signs of splenomegaly, hepatomegaly, or jaundice and was not being transfused.
More than a decade after the initial identification of this family, further blood tests and a medical examination were carried out as part of this study on the surviving members of the family who Subject II.1 (currently 49 years old) presented signs of mild jaundice, paleness, and fatigue. He had splenomegaly and hepatomegaly, with the spleen and liver palpable at 4 cm and 2 cm below the costal margin, respectively. He was also suffering from osteoporosis but had never presented with thrombosis, ulcers, or obvious organ damage. His latest new blood tests (Table 2) Proteins-Biuret (g/dl) 6.8 6.6-8.3
Albumins (ALB; g/dl) 4. 
| Genetic features
A pedigree analysis showed a dominant pattern of inheritance for the high HbF phenotype in the family (Figure 1a) . Initially all individuals of the family were screened for the presence of mutations at the HBA1, HBA2 (α-globin), and HBB (β-globin) genes. The sequencing results of the HBA1 and HBA2 genes were normal. HBB sequencing revealed the presence of the IVS1-110; HBB: c.93-21G>A
(NM_000518.5:c.93-21G>A) mutation ( Figure 1a ; Table 1 ), as expected. The unusually high levels of HbF in some family members could be linked to in-cis variations at the β-globin locus (Weatherall, 2001 ). However, sequencing analysis of the HBG1 and HBG2 (γ-globin) gene promoters revealed no mutations. In addition, multiplex ligation probe analysis (MLPA) identified no deletions in the β-globin locus, thus excluding deletional HPFH delta-beta thalassemia as a possible cause for the high levels of HbF detected (Table 1 ). 
| Evaluation and structural analysis of the novel p.Ser323Leu mutation
To obtain an indication of the relative importance of the novel mutation, we carried out an in silico prediction of the functional outcome of the amino acid change on the protein structure. We also performed an amino acid sequence alignment of the second zinc finger region of KLF1 to multiple species. Prediction analysis using the PredictSNP tool revealed that the p.Ser323Leu mutation is likely to have a deleterious effect on protein function, whereas the known variant p.Ser102Pro (Figure 2a ) was shown to have a neutral effect.
Alignment analysis showed the serine residue at position 323 to be highly conserved (Figure 2b ), suggesting that mutations at this residue might affect the KLF1 protein mechanistically and/or structurally.
In silico structural analyses of the KLF1 zinc finger domain containing the p.Ser323Leu mutation and the wild-type KLF1 zinc finger domain offer a possible explanation as to how the mutation may affect the binding activity of the conserved zinc finger 2 domain. The serine at position 323 of KLF1 is directed towards the target DNA. The substitution of the relatively small, polar hydrophilic serine residue by the nonpolar, hydrophobic leucine residue seems not to alter the structure of the rest of the zinc finger domain but mainly affects the distance of the side chain of residue 323 from the DNA backbone. In silico modeling shows that the distance between the mutant 323Leu and the DNA backbone is increased due to the shortness of the leucine side chain compared with the wild-type 323Ser. In addition, the change from a polar serine to a nonpolar leucine residue might affect the formation of hydrogen bonds crucial for the stabilization of the protein itself or transcription factor complexes ( Figure   2c ). However, it must be stressed that the effect of the mutation on the binding specificity and affinity of KLF1 can only be ascertained using functional studies such as electrophoretic mobility shift assays (EMSA).
3.5 | Characterization of the effect of the p.Ser323Leu mutation on γ-globin production However, to get a more thorough picture of the effects of this mutation, more sensitive protein quantitation methods should be used, where the interactions of the mutant KLF1 with target genes other than BCL11A, such as ZBTB7A/LRF and Sox6 (Norton et al., 2017; Xu et al., 2010) , that also play a role in globin gene regulation by KLF1, need to be investigated.
| DISCUSSION
In this study we report a novel mutation in the KLF1 transcription factor identified in the heterozygous state in two siblings. These individuals are homozygous for a severe β-globin mutation (IVS1-110;
HBB: c.93-21G>A) which would normally result in a β-thalassemia major phenotype. However, neither sibling requires blood transfusions. Two additional members of this family, bearing the same KLF1 mutation, show elevated levels of HbF.
Subject II.1, who carries the novel KLF1 mutation (p.Ser323Leu) and is homozygous for IVS1-110, showed hematological characteristics akin to a β-thalassemia carrier with reduced Hb, HCT, MCV, and MCH levels and complete transfusion independence. He had no leg ulcers and never suffered from thrombosis. However, his condition was more severe than a carrier's as indicated by the presence of splenomegaly, hepatomegaly, osteoporosis, and hemolysis-related indications such as jaundice and high levels of bilirubin.
His overall clinical severity appears to fall between a β-thalassemia carrier and β-thalassemia intermedia (TI) patient. The second member of this family with the same KLF1 and HBB genotype (subject II.2) was also transfusion independent but had passed away at the age of 62 due to cancer.
The study by Liu et al. (2014) causing the observed differences in the patients' phenotype.
The p.Ser323Leu mutation is located on the second zinc finger of the KLF1 protein. KLF1 is a transcription factor that plays a crucial role in erythropoiesis and regulates the expression of several erythroid-specific genes (Perkins et al., 2016; Tallack et al., 2010; Yien & Bieker, 2013) . In addition, KLF1 is an important regulator of the levels of HbF as it was demonstrated to be a positive transcriptional regulator of BCL11A (Borg et al., 2010; Zhou et al., 2010) . Most, though not all, known KLF1 mutations have been associated with elevated HbF levels in humans. A number of KLF1 mutations have been shown to be responsible for diseases associated with ineffective erythropoiesis or to have no effect on γ-globin expression (Borg, Patrinos, Felice, & Philipsen, 2011; Waye & Eng, 2015) .
Several KLF1 mutations have been identified that map close to the novel p.Ser323Leu described here. The p.Glu325Lys mutation, which is also found on the second zinc finger of KLF1, has been shown to cause congenital dyserythropoietic anemia type IV (CDA IV), a rare and severe red blood cell disorder (Arnaud et al., 2010; Jaffray et al., 2013) . The neighboring p.Ser323Leu mutation has no such deleterious effects and appears to ameliorate, to a certain degree, the clinical phenotype of β-thalassemia major. Both mutations cause high levels of HbF. A recently described mutation at the same amino acid (p.Ser323Trp) is responsible for the rare In(Lu) blood group phenotype. (Kawai et al., 2017) The (p.Ser323Leu) mutation is also the likely cause of the Lu(a-,b-) phenotype identified in subjects II.1 and III.2.
Exogenous expression of the p.Ser323Leu KLF1 mutant in healthy human erythroid progenitor cells depleted of the endogenous KLF1 results in an increase in the levels of γ-globin, confirming our observations of elevated HbF levels in the family under study.
Similar findings of increased levels of γ-globin were also observed for the p.Glu325Lys mutation. Arnaud et al. (2010) suggested that the p.Glu325Lys mutation has increased binding affinity to DNA and operates in a dominant negative fashion compared to the wild-type KLF1, resulting to the CDA IV phenotype. However, Singleton et al. (2011) proposed that the disease phenotype is caused by a lower affinity of the p.Glu325Lys mutation, leading to the formation of p.Glu325Lys KLF1 transcription complexes that are easily dissociated from gene promoters in an antagonistic way.
The observed increases in γ-globin gene expression seen in the family under investigation may be brought about by changes in the DNA-binding affinity and specificity of the mutant KLF1 molecule, and thus altered expression of KLF1 target genes. This hypothesis is proposed based on the location of the novel mutation in the second zinc finger domain of the protein, which is part of the DNA-binding domain. The in silico and in vitro work presented here hint at, but do not prove this hypothesis. Definitive proof can only be provided by additional EMSA and binding assays.
The effect of this mutation seems not to be mediated through changes in the level of expression of BCL11A, However, we cannot discount the possibility that more sensitive techniques such as mass Although the use of appropriate controls can overcome some of these issues, the recently developed human umbilical cord bloodderived erythroid progenitor 2 (HUDEP2) (Kurita et al., 2013) gene and the HBS1L-MYB intergenic region Thein et al., 2007) . In the family case study presented here, there is no variation at the HBG1 and HBG2 gene promoters and the associated SNPs at the BCL11A and HBS1L-MYB loci do not segregate with the high HbF levels ( Table 1 ). The differences at the HbF levels in these individuals might be due to as yet unknown genetic modifiers involved in the regulation of γ-globin gene expression. In our family case we could not conclude if the p.Ser323Leu KLF1 mutation causes borderline HbA 2 levels (Perseu et al., 2011) because all individuals having the KLF1 mutation were also heterozygous for the IVS1-110;
HBB: c.93-21G>A mutation ( Figure 1a ; Table 1 ), which is known to increase the HbA 2 levels (Steinberg & Adams, 1991) .
Although the availability of limited sample quantities of peripheral blood for this experiment allowed the performance of only the most vital hematological and biochemical tests, it is hoped that in the future sufficient material will be collected to allow the generation of HEP cell cultures from subject II.1. This will enable additional functional studies to be performed on the novel p.Ser323Leu KLF1 We would like to thank Dr Panagiota Papasavva for valuable discussions regarding the patient data.
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